mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for RAB26
Gene summary
Basic gene Info.Gene symbolRAB26
Gene nameRAB26, member RAS oncogene family
CytomapUCSC genome browser: 16p13.3
Type of geneprotein-coding
DescriptionRas-related oncogene proteinras-related protein Rab-26
Modification date20141207
dbXrefs MIM : 605455
Ensembl : ENSG00000167964
HPRD : 05676
Vega : OTTHUMG00000128829
ProteinUniProt: Q9ULW5
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_RAB26
BioGPS: 25837
PathwayNCI Pathway Interaction Database: RAB26
Pathway Commons: RAB26
ContextiHOP: RAB26
ligand binding site mutation search in PubMed: RAB26
UCL Cancer Institute: RAB26
Assigned class in mutLBSgeneDBC: This gene just belongs to mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez

Ligand binding site mutations for RAB26
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for RAB26
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for RAB26 from PDB

Differential gene expression and gene-gene network for RAB26
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of RAB26 and the right PPI network was created from samples without mutations in the LBS of RAB26. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for RAB26
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for RAB26
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of RAB26 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS

Conservation information for LBS of RAB26
Multiple alignments for Q9ULW5 in multiple species
LBSAA sequence# speciesSpecies
A182NKVDSAHERVV1Homo sapiens
A182NKVDSAQERAV1Bos taurus
A182NKVDSTQDRVV1Mus musculus
A182NKVDSTQERVV1Rattus norvegicus
A208FMETSAKTGLN2Homo sapiens, Bos taurus
A208FMETSARTGLN1Mus musculus
A208FMETSAKSGLN1Rattus norvegicus
C78GVGKTCLLVRF4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
D180LGNKVDSAHER1Homo sapiens
D180LGNKVDSAQER1Bos taurus
D180LGNKVDSTQDR1Mus musculus
D180LGNKVDSTQER1Rattus norvegicus
F88FKDGAFLAGTF4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
F93FLAGTFISTVG4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
G73LVGDSGVGKTC4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
G75GDSGVGKTCLL4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
K178MLLGNKVDSTQ2Mus musculus, Rattus norvegicus
K178MLLGNKVDSAH1Homo sapiens
K178MLLGNKVDSAQ1Bos taurus
K209METSAKTGLNV2Homo sapiens, Bos taurus
K209METSARTGLNV1Mus musculus
K209METSAKSGLNV1Rattus norvegicus
K76DSGVGKTCLLV4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
N177LMLLGNKVDSA2Homo sapiens, Bos taurus
N177LMLLGNKVDST2Mus musculus, Rattus norvegicus
S207PFMETSAKTGL2Homo sapiens, Bos taurus
S207PFMETSARTGL1Mus musculus
S207PFMETSAKSGL1Rattus norvegicus
S72MLVGDSGVGKT4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
S95AGTFISTVGID4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
T77SGVGKTCLLVR4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
T96GTFISTVGIDF4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus
V74VGDSGVGKTCL4Homo sapiens, Bos taurus, Mus musculus, Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas